You are here

Soliris

Alexion shares slide on Amgen patent challenge to top-seller

Biopharma Dive

Fri, 08/30/19 - 01:00 pm

inter partes review

Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?

Fierce Pharma

Fri, 07/26/19 - 11:05 am

Alexion’s Soliris follow-up Ultomiris snares EU approval

Pharmaforum

Sun, 07/7/19 - 11:13 am

Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication

Endpoints

Fri, 06/28/19 - 12:36 pm

autoimmune disease

FDA Action Alert: Regeneron, Sanofi, Celgene

BioSpace

Mon, 06/24/19 - 07:27 pm

Acer Therapeutics

Dova Pharmaceuticals

Nabriva Therapeutics

3 Drug Stocks That Could Win From Key FDA Approvals in June

Motley Fool

Tue, 06/4/19 - 10:59 am

Amag Pharmaceuticals

Mark Your Calendar For These June PDUFA Dates

Yahoo/Benzinga

Sat, 06/1/19 - 12:52 pm

Amag Pharmaceuticals

Acer Therapeutics

Go or no go? Merck, Regeneron and Alexion await US expansion

EP Vantage

Thu, 05/30/19 - 09:39 am

Dova Pharmaceuticals

Alexion gets off to the races with key Ultomiris, Soliris launches

Fierce Pharma

Mon, 04/29/19 - 10:25 am

14 Drugs Earn Billions for These Massachusetts Biotechs

BioSpace

Wed, 03/6/19 - 09:59 am

Vertex Pharmaceuticals

Ironwood Pharmaceuticals

Alexion aims for fourth rare disease use for blockbuster Soliris

Pharmaforum

Tue, 02/26/19 - 09:36 am

Alexion Pharmaceuticals

neuromyelitis optica spectrum disorder

Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris

Stat

Fri, 12/21/18 - 11:51 am

Alexion Pharmaceuticals

Ra Pharma files $100M round as Soliris rival clears phase 2 trial

Fierce Biotech

Tue, 12/11/18 - 11:49 am

clinical trials

myasthenia gravis

Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M

Endpoints

Mon, 09/24/18 - 03:33 pm

clinical trials

How badly does Alexion want its Soliris follow-on? Enough to use a rare fast pass

Biopharma Dive

Tue, 06/19/18 - 09:40 pm

priority review

Alexion's follow-on stacks up to Soliris

Biopharma Dive

Fri, 03/16/18 - 11:19 am

paroxysmal nocturnal hemoglobinuria

Alexion turns focus to rebuilding pipeline amid restructuring

Biopharma Dive

Thu, 02/8/18 - 11:49 pm

Prepping PhIII for Soliris rival, Apellis rides a boisterous market to a $150M IPO

Endpoints

Sat, 11/11/17 - 10:59 am

Alexion cutting 600 jobs and moving headquarters in major shakeup

Stat

Tue, 09/12/17 - 10:05 am

Alexion bolsters Soliris patent defense

BioPharma Dive

Thu, 08/17/17 - 09:59 am

Pages